

## **INTERVIEW: Feed Enzyme Firm BRI Optimistic About 2014 Xylanase Product Launch**

Source: Feedinfo News Service  
(dated 03/12/2013)

**3 December 2013 – Several months ago, as part of its commitment to developing high-quality enzymes, North Carolina-based agricultural biotechnology firm BioResource International (BRI) announced the upcoming launch of Xylamax(TM)360-P, a heat-stable mono-component xylanase, in select markets with select partners.**

High feed costs have driven more interest in North America and worldwide for feed enzymes. Today, xylanases are gaining market acceptance and are poised for more growth. According to BRI's President and CEO, Dr. Giles Shih, the launch of Xylamax™360-P is a timely one.

"We believe enzymes are gaining acceptance in the market as a valued feed additive and that this sector of the market will continue to grow", he told Feedinfo News Service, pointing out that building a sustainable feed enzyme business depends on delivering consistent performance and building long-term value, regardless of feed cost gyrations.

"We are in the process of lining up the right partners for the markets we have selected to launch Xylamax™360-P, which will most likely be the first quarter of 2014", he said.

Dr. Shih added that BRI will focus initially on the geographic markets with the most streamlined regulatory processes, followed by those that require more time and resources to complete the registration process.

Providing a bit of background on the new product, BRI's CEO wished to stress that his company's core competency is enzyme research and development.

"With the ever-increasing cost of feed, producers are looking for ways to limit the cost of feed while still maintaining a high level of production in their livestock. We believe enzymes are part of the solution and have proven that concept with our market-leading thermostable protease feed enzyme, Versazyme®. BRI is constantly looking for ways to expand our product portfolio and we have now developed a xylanase product that is inherently thermotolerant (not coating-dependent) and could be applied as a dry product to the feed prior to pelleting, which is easier to manage than liquid application", he commented.



**Dr. Giles Shih**  
President & CEO  
BioResource International (BRI)

“BRI also leveraged its strategic partnership with a key supplier to develop the cost-effective process for producing Xylamax™360-P”, he added.

According to Dr. Shih, BRI’s Xylamax™360-P has been tested in wheat-containing diets and in corn-soybean diets and has performed well under those varied conditions (the “360” in the Xylamax™360-P stands for “all around performance and versatility”).

For example, a recent broiler feeding trial conducted at Texas A&M University demonstrated that Xylamax™360-P released over 100 kcal per kg of energy in a standard corn-soy diet. BRI’s CEO went on to say that the results of this trial will be presented at the International Poultry Scientific Forum in Atlanta, Georgia, in January 2014.

When asked how Xylamax™360-P differs from other mono-component xylanases available in the market, Dr. Shih simply highlighted the product’s scientifically-backed and proven credentials.

“Every xylanase supplier will tell you that their products deliver superior performance and have the highest activity. We would be remiss if we did not claim the same for Xylamax™360-P!” he commented.

“However, we have always believed in the principle of letting the animal trial data speak for themselves. And the data so far tell us the following: Xylamax™360-P delivers xylanase activity to the animal when and where it needs it, as shown by improved feed digestibility in the gut; Xylamax™360-P demonstrates high thermostability, allowing for pre-pellet mixing in the feed; and Xylamax™360-P releases over 100 kcal of energy in corn-soy diets”.

The market for xylanase feed enzymes in North America and around the world is growing and has become increasingly price-competitive. In this scenario, BRI believes that it has a competitive edge, thanks to a cost-effective process for producing Xylamax™360-P, as well as more than sufficient production capacity for Xylamax™360-P to meet a robust demand in the market.

In addition, Dr. Shih is convinced that feed enzymes that deliver consistent performance with a good value proposition, such as those manufactured by BRI, will continue to be in demand in the longer term.